Fintel reports that on November 24, 2025, Guggenheim maintained coverage of Pfizer (NYSE:PFE) with a Buy recommendation.

Pfizer offers strong dividends, solid cash flow coverage, discounted value and key risks from patent cliffs, pricing and ...

Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

(NYSE:PFE) is one of the stocks Jim Cramer recently shed light on. Cramer highlighted some of the stock’s possible catalysts, ...

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Pfizer (PFE) shares have shown resilience, with a modest uptick over the past week and month. Investors are keeping an eye on the stock’s performance as the company navigates market trends and ...

Pfizer Inc. (NYSE: PFE) is one of the best undervalued stocks to buy under $50. Pfizer Inc. (NYSE:PFE) received a rating update from TD Cowen analyst Steve Scala on November 4, who maintained a Hold ...

Johnson & Johnson’s JNJ stock has risen 16.7% in the past three months. A lot of this price increase is due to strong ...

With roots dating back to 1891 and a portfolio that includes the blockbuster cancer immunotherapy Keytruda, Merck (NYSE:MRK) ...